Systematic review and meta-analysis demonstrate the potential of CBD in reducing seizure frequency in Epilepsy

Epilepsy, a chronic neurological disease, affects a substantial number of individuals globally, with a significant subset of patients demonstrating an unsatisfactory response to conventional antiepileptic medications. Recent research has increasingly focused on cannabidiol (CBD), a non-psychotropic compound derived from the Cannabis sativa plant, as a potential therapeutic option for patients with drug-resistant epilepsy. present systematic review and meta-analysis evaluates the effectiveness of CBD in reducing the frequency of epileptic seizures, highlighting the main conclusions, methodologies and future directions for clinical practice.

Epilepsy is a condition characterized by recurrent, unprovoked seizures, which can significantly impact patients' quality of life. Although up to 80% of patients achieve seizure control with standard monotherapy, approximately 20% remain drug-resistant. These patients continue to experience frequent and unpredictable seizures that disrupt daily activities, limit functional capacity, and burden caregivers. The search for alternative treatments has led physicians and researchers to investigate the anticonvulsant properties of cannabidiol.

Cannabidiol presents itself as a particularly promising therapeutic option due to its multiple benefits, including anticonvulsant, neuroprotective, and even antidepressant effects, without the psychoactive properties typically associated with other cannabis-derived compounds. Given the limited treatment options for drug-resistant epilepsy, CBD's potential to significantly reduce seizure frequency is generating substantial interest in the medical community.

A rigorous systematic review approach

To determine the true effectiveness of CBD in reducing seizures in drug-resistant epilepsy, researchers used systematic reviews and meta-analyses guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol. This methodical approach ensures that the data compiled across multiple studies are robust and reliable.

Research strategy and study selection

A meticulous search was conducted across multiple databases, including PubMed/MEDLINE, Google Scholar, and Scielo, using specific keywords such as "Cannabidiol," "Epilepsy," and "Drug-Resistant Epilepsy." The search was restricted to publications in English and Portuguese within a defined period, ensuring the relevance and timeliness of the data. Studies were included if:

• Involved patients with drug-resistant epilepsy.
• Implementation of CBD as a new intervention.
• – They used randomized and double-blind clinical trial models.
• Reported quantitative data that allowed the calculation of changes in seizure frequency.

After removing duplicates and applying strict inclusion criteria, a few high-quality studies were selected for detailed analysis.

Data extraction and statistical analysis

Data from each study were extracted using standardized forms. Key variables included study design, number of participants, dosage variations, seizure frequency before and after treatment, and any reported adverse effects. A random-effects model was used to analyze changes in seizure frequency, providing a comprehensive representation of the data in a forest plot. Using advanced statistical software, such as RevMan® 5.4, facilitated the generation of reliable P-values ​​and ensured consistency across the analyzed studies.

Impact of cannabidiol on seizure frequency

The data compiled from the selected studies demonstrated promising results for patients treated with CBD. On average, subjects receiving cannabidiol experienced an approximately 41% reduction in the number of seizures, compared to an 18% reduction in the placebo groups. This result indicates a 127% higher response rate among patients treated with CBD.

Dosage and efficacy comparisons

A dose-dependent response to CBD has been observed. Studies comparing different dosages (typically 10 mg/kg/day versus 20 mg/kg/day) have shown that a higher dosage generally provided a 12% improvement in seizure control. However, it is essential to weigh the benefits of a higher dose against the increased risk of adverse effects. The most common side effects reported included elevated liver enzymes, sedation, and decreased appetite. These adverse effects highlight the need for careful monitoring, especially in patients with pre-existing liver problems.

Subgroup analyses: Dravet and Lennox-Gastaut syndromes

The studies analyzed focused predominantly on patients with Dravet syndrome and Lennox-Gastaut syndrome, two severe forms of epilepsy that demonstrate notable resistance to conventional treatments. In these subgroups, the response to CBD was statistically significant, although some variability in results was observed. For example, while some patients experienced drastic reductions in seizure frequency (even seizure-free), others showed minimal or no improvement. This heterogeneity suggests that individual patient factors may influence the effectiveness of CBD treatment.

Balance between efficacy and safety

While the effectiveness of CBD in reducing seizure frequency is promising, there are several aspects that deserve further discussion.

Adverse effects and safety monitoring

The predominant concern associated with CBD treatment is its potential for adverse effects. The systematic review demonstrated that a significant proportion of patients experienced side effects, including drowsiness, loss of appetite, and diarrhea. Elevated serum transaminases, often up to three times above baseline levels, indicate the need for continuous monitoring of liver function during CBD treatment. Patients with underlying liver disease may require alternative management strategies, and regular enzyme monitoring is recommended during the first few months of treatment.

Variability in patient response

The variability in treatment response in patients with drug-resistant epilepsy remains a complex issue. Some patients, designated "good responders," experienced a reduction in seizure frequency of over 50%, while others experienced less pronounced benefits. This heterogeneity highlights the imperative need for personalized treatment plans and further research to identify predictive factors that can help determine which patients are most likely to benefit from CBD therapy.

Methodological considerations

The similarity of study methodologies among the analyzed trials enhances the reliability of the meta-analysis. Most studies included an initial measurement period, followed by a structured treatment phase with controlled dose increases and a defined tapering plan. However, the notable reduction in seizures observed in the placebo groups raises questions about the potential influence of the placebo effect and patient expectations. The rigorous double-blind design of these studies was intended to mitigate such biases, but the results suggest that additional data collection and analysis methods could further refine our understanding of CBD's efficacy.

The need for long-term studies

All of the studies analyzed involved relatively short treatment periods (typically about 12 weeks), which limits our understanding of CBD's long-term safety and efficacy. Future research should focus on longer treatment periods to assess whether CBD's benefits are maintained over time and to better understand any cumulative adverse effects that may arise from prolonged use.

Clinical implications and future directions

Given the compelling evidence supporting CBD's role in reducing seizure frequency, there is a strong case for its inclusion in new treatment protocols for drug-resistant epilepsy. However, several challenges must be addressed before CBD can be widely adopted in clinical practice.

Integration of CBD into treatment algorithms

Despite its promising efficacy, CBD's adoption into standard treatment guidelines remains limited in many regions. In countries like Brazil, for example, CBD use is currently managed on a case-by-case basis and is not integrated into official treatment algorithms. Regulatory and cost hurdles, as well as the need for imports, significantly complicate its implementation. Therefore, health authorities should consider investing in local research and policy reforms to facilitate wider access to CBD as part of public health systems.

Identification of predictive response markers

Optimizing treatment outcomes depends on identifying biomarkers or clinical indicators that predict a positive response to CBD. Understanding individual differences in treatment response, which can be significant, can lead to the development of more personalized and effective therapeutic strategies.

Improve accessibility and reduce costs

The economics of CBD therapy are equally crucial. The high cost associated with CBD, compounded by issues related to importation and regulatory approval, limits its accessibility. Therefore, public health systems and policymakers must act in concert to negotiate more advantageous prices, simplify regulatory processes, and eventually include CBD on the list of essential medicines to facilitate patient access.

A promising avenue for seizure control

The current body of evidence suggests that cannabidiol provides a significant reduction in seizure frequency in patients with drug-resistant epilepsy. With an average reduction of over 40% in seizure count compared to placebo, CBD stands out as a potent adjunctive treatment. However, the balance between efficacy and safety must be carefully managed, particularly in light of the dose-dependent adverse effects observed.

Further research is needed to extend these results to longer treatment periods and to determine optimal dosing strategies that maximize benefits and minimize risks. Furthermore, variability in patient response requires a personalized approach to treatment, potentially guided by predictive biomarkers.

Ultimately, as more clinical data becomes available and regulatory barriers are addressed, cannabidiol may emerge as a cornerstone in the treatment of drug-resistant epilepsy, offering hope for a better quality of life for millions of patients worldwide.

By synthesizing the latest research and providing a comprehensive analysis of CBD's potential as an antiepileptic agent, this systematic review and meta-analysis highlights both the promise and challenges of integrating cannabidiol into epilepsy treatment protocols. As we move forward, a collaborative effort between researchers, clinicians, and policymakers will be essential to fully harness the benefits of CBD for those who need it most.

Read the review in the document below:
s42494-024-00191-2

____________________________________________________________________________________________________

____________________________________________________________________________________________________

What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!

João Xabregas

More postsBio

With a professional background in CAD technical drawing (2D and 3D), João Xabregas is an activist and advocate for all uses and applications of cannabis. He discovered and entered the world of cannabis during his youth, where he developed a special interest in the cultivation of the plant, which led him on a journey of self-learning through the world of cannabis that continues to this day. His adventures linked to cannabis cultivation began with the same goal as many others: to be able to guarantee the quality and eliminate any possible risks to his health of what he consumed, as well as to avoid any type of dependence on the illicit market. However, he quickly began to view the world of cannabis and everything related to it with a very different perspective. He admits the enormous passion he has for the most persecuted plant in the world and about which he is always willing to write and have a good conversation.

• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Cannabizetol: New cannabinoid may have antioxidant and anti-inflammatory benefits for the skin
• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Study reveals that inability to drive after using cannabis can last more than five hours
• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  Portugal: New cannabis seizure in Grândola exposes yet another illegal trafficking operation disguised as a medicinal facility
• João Xabregas

  https://cannareporter.eu/author/joaoxabregas/

  SOMAÍ and Universidade Lusófona publish peer-reviewed study to improve practices in the production of full-spectrum cannabis oils